The medical term polycystic ovary syndrome (PCOS) has been officially replaced with polyendocrine metabolic ovarian syndrome (PMOS) following a 14-year international review. The change, published in The Lancet on Tuesday, emerged from a global collaboration involving clinicians, researchers, and 14,360 patients across multiple continents. Experts used modified Delphi techniques, nominal group workshops, and implementation studies to reach consensus on the new name. PMOS affects an estimated 10 to 13 per cent of women during their reproductive years, with up to 70 per cent of cases undiagnosed globally, according to the World Health Organisation. The condition involves hormonal imbalances, elevated androgen levels, and endocrine dysfunction, leading to irregular menstrual cycles, ovulation difficulties, pelvic pain, and heavy bleeding. Additional symptoms include acne, oily skin, excessive facial or body hair, and scalp hair thinning. PMOS is a leading cause of anovulation and infertility worldwide. Long-term risks include gestational diabetes, pregnancy-related hypertension, type 2 diabetes, cardiovascular disease, high blood pressure, cholesterol abnormalities, and endometrial cancer. Emotional and psychological challenges also accompany the physical symptoms, significantly affecting quality of life. The previous name, PCOS, was deemed scientifically inaccurate because ovarian cysts are not consistently present. Experts stated the old term contributed to delayed diagnosis, fragmented treatment, and patient stigma. The new name reflects the interconnected endocrine, metabolic, and ovarian aspects of the disorder, including insulin resistance, obesity, and diabetes risk. Helena Teede, lead researcher at the Monash Centre for Health Research, said the earlier framing led to inadequate care. "It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition," she said. She described the name change as a necessary step after advances in global guidelines. The transition from PCOS to PMOS will be implemented over three years with support from health institutions.
The renaming of PCOS to PMOS exposes a long-standing gap between medical terminology and clinical reality, as ovarian cysts are not consistently present in affected patients. This shift corrects a misleading label that contributed to misdiagnosis and inadequate treatment for millions of women. For Nigerian women, many of whom face limited access to reproductive healthcare, a more accurate diagnosis framework could improve recognition and management of the condition. However, without corresponding investment in local awareness and specialist training, the new term may remain a global update with little local impact.
💡 NaijaBuzz Take is AI-assisted editorial opinion, not established fact. Full disclaimer →
